Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B-3E06
- Development stage
- Phase 1
- Lead developer
- Yifan Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
B-3E06 is a recombinant human growth hormone (rhGH) biologic candidate being developed by Yifan Pharmaceutical for the treatment of growth hormone deficiency (GHD). Currently in Phase 1 clinical development, B-3E06 is designed to supplement or replace endogenous growth hormone in patients with insufficient levels. The drug functions as an agonist at the growth hormone receptor (GHR), triggering signaling pathways that stimulate the production of insulin-like growth factor 1 (IGF-1), which in turn promotes linear growth, skeletal development, and metabolic regulation. B-3E06 is part of Yifan's pipeline of biosimilar or bio-better candidates, intended to provide a therapeutic alternative to established somatropin products.
02
Targets
GHR (Growth hormone receptor)
Beyond the preview
Go deeper on B-3E06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B-3E06.